Diagnostic characteristics, treatment outcomes, and prognostic factors in glucagonomas
Tumour grade, metastases, and NME at diagnosis influence OS in glucagonoma. Surgery is associated with the best PFS as first-line therapy, while <sup>177</sup>Lu-DOTATATE PRRT effectively controls disease progression. Further studies are needed to optimise treatment sequencing for advanced glucagonoma.
Authors
- Shaunak Navalkissoor (ORCID: https://orcid.org/0000-0003-2886-9691)
- Dalvinder Mandair (ORCID: https://orcid.org/0000-0002-5237-8641)
- Alexander Branton
- Christos Toumpanakis (ORCID: https://orcid.org/0000-0002-1152-7727)
- Martyn Caplin (ORCID: https://orcid.org/0000-0003-0177-1352)
- Gopinath Gnanasegaran
- Juliana Barreiros Porto (ORCID: https://orcid.org/0000-0001-9164-2719)
- Ashley Barry Grossman (ORCID: https://orcid.org/0000-0003-1176-6186)
- Eleni Armeni (ORCID: https://orcid.org/0000-0003-3310-1521)
- Aimee R. Hayes (ORCID: https://orcid.org/0000-0003-4417-7716)
- Aspasia Manta (ORCID: https://orcid.org/0000-0002-3420-1420)
- Ann‐Marie Quigley
Institutions
- Royal Free London NHS Foundation Trust (GB)
- The Royal Free Hospital (GB)
- European Neuroendocrine Tumor Society (DE)
- University General Hospital Attikon (GR)
- University College London (GB)
- Athens State University (US)
Publication Details
- Journal
- Endocrine Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1530/eo-24-0083
- Citations
- 1
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.35